SCHEMBL6791534

SCHEMBL6791534

C/C(=C/C(=O)Nc1cccc(C(=O)O)c1C(=O)O)c1ccc2ccccc2c1

nearest known ligand 0.82

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.82
KDM4E B2RXH2 1/20 0.47
SLC16A3 O15427 1/20 0.44
LTB4R Q15722 1/20 0.44
DHODH Q02127 1/20 0.44
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
NR1H4 Q96RI1 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
POLB P06746 1/20 0.40
LPAR2 Q9HBW0 1/20 0.40
LPAR3 Q9UBY5 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30760782 0.90 TERT (1.00) TERTKDM4ESLC16A3LTB4RDHODH
SCHEMBL4022937 0.90 TERT (1.00) TERTKDM4ESLC16A3LTB4RDHODH
SCHEMBL29362821 0.90 TERT (1.00) TERTKDM4ESLC16A3LTB4RDHODH
SCHEMBL16964998 0.90 TERT (1.00) TERTKDM4ESLC16A3LTB4RDHODH
SCHEMBL29966843 0.90 TERT (1.00) TERTKDM4ESLC16A3LTB4RDHODH
SCHEMBL29355750 0.90 TERT (1.00) TERTKDM4ESLC16A3LTB4RDHODH
SCHEMBL6789273 0.87 TERT (0.69) TERTLTB4RNPC1RAB9AMEN1
SCHEMBL6783614 0.85 TERT (0.81) TERTKDM4ESLC16A3LTB4RDHODH
SCHEMBL6784790 0.84 TERT (0.68) TERTKDM4ELTB4RNPC1RAB9A
SCHEMBL6783732 0.83 TERT (0.85) TERTKDM4ESLC16A3LTB4RDHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885KDM4E 1243/4885SLC16A3 1630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.